Organisms | Evidence |
---|---|
Mus musculus (house mouse) | |
Rattus norvegicus (Norway rat) | |
Homo sapiens (human) | |
Drosophila melanogaster (fruit fly) | |
Streptococcus pneumoniae |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
B3GALT2 | UDP-Gal |
|
Lemieux |
|
Lemieux | |
B4GALT2 | UDP-Gal |
|
Benzyl-[beta] |
|
Benzyl-[beta] | |
B4GALT1 | UDP-Gal |
|
R |
|
R | |
B3GALT5 | UDP-Gal |
|
R |
|
R |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
B4GALT3 | UDP-Gal |
|
Benzyl-[beta] |
|
Benzyl-[beta] | |
B4GALT4 | UDP-Gal |
|
[beta]-1-Benzl |
|
[beta]-1-Benzl | |
B3GALT2 | UDP-Gal |
|
Lemieux |
|
Lemieux | |
B4GALT4 | UDP-Gal |
|
[beta]-1-4-methyl-umbelliferyl |
|
[beta]-1-4-methyl-umbelliferyl |
Pathway Name | Organism |
---|---|
E.coli O58 | Escherichia coli |
E.coli O64 | Escherichia coli |
E.coli O74 | Escherichia coli |
E.coli O75 | Escherichia coli |
E.coli O78 | Escherichia coli |
E.coli O82 | Escherichia coli |
E.coli O83 | Escherichia coli |
E.coli O85 | Escherichia coli |
E.coli O88 | Escherichia coli |
E.coli O91 | Escherichia coli |
RES 1b:b-dglc-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
35288161 | OGT as potential novel target: Structure, function and inhibitors | Zhang N | 2022 Apr 25 |
|
35547740 | Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron | Casasnovas JM | 2022 Apr 25 |
|
35324257 | Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 | Zhou T | 2022 Apr 22 |
|
35443747 | Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses | Wang Y | 2022 Apr 21 |
|
35357812 | O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and alpha-Synuclein Proteinopathies | Permanne B | 2022 Apr 20 |
|
35139364 | Conformational transitions and ligand-binding to a muscle-type nicotinic acetylcholine receptor | Zarkadas E | 2022 Apr 20 |
|
35440630 | Structure, gating, and pharmacology of human CaV3.3 channel | He L | 2022 Apr 19 |
|
35427157 | Cln5 represents a new type of cysteine-based S -depalmitoylase linked to neurodegeneration | Luebben AV | 2022 Apr 15 |
|
35299116 | From tryptophan-based amides to tertiary amines: Optimization of a butyrylcholinesterase inhibitor series | Meden A | 2022 Apr 15 |
|
35291264 | RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants | Liang Q | 2022 Apr 15 |
|
Title | Authors | Source | Publication Date | PubMed ID |
---|---|---|---|---|
Dynamic glycosylation of the transcription factor CREB: a potential role in gene regulation. |
|
J Am Chem Soc | 2003 Jun 4 | 12769553 |
Effect of okadaic acid on O-linked N-acetylglucosamine levels in a neuroblastoma cell line. |
|
Biochim Biophys Acta | 1999 Oct 18 | 10572927 |
Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. |
|
J Biol Chem | 1999 Nov 5 | 10542233 |
An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. |
|
J Biol Chem | 1999 May 21 | 10329728 |
Vertebrate lens alpha-crystallins are modified by O-linked N-acetylglucosamine. |
|
J Biol Chem | 1992 Jan 5 | 1730617 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025